Retatrutide stories

Jul 23, 2026

Eli Lilly's retatrutide shows positive Phase 3 results, plans Q1 2027 FDA application

Eli Lilly announced positive results from two additional Phase 3 trials of its experimental obesity drug retatrutide (a 'triple-G' GLP-1 receptor agonist), showing it did not increase overall heart risk. The company plans to submit an FDA application in Q1 2027.

Jul 23, 2026·3 sources

Jun 23, 2026

Eli Lilly Grants Compassionate Use Access to Experimental Obesity Drug Retatrutide for Single Patient

Eli Lilly provided its experimental 'triple-G' weight loss drug retatrutide to a 79-year-old patient through the FDA's compassionate use program, marking an extremely rare instance of pre-approval access to an obesity medication.

Jun 23, 2026·2 sources

Top claims

▪The most common side effects of retatrutide in the latest Phase 3 trials were nausea and diarrhea.
▪Earlier studies of retatrutide had raised questions about a possible increase in heart rhythm abnormalities.
▪A cardiovascular safety trial in nearly 2,000 people with obesity and heart disease was not powered to study cardiovascular outcomes.

Subtopics

Eli Lilly GLP-1 receptor agonists Clinical trials GLP-1 medications Weight management US health policy & drug pricing

Bioethicists of life extension

Related timelines

Retatrutide stories

Eli Lilly's retatrutide shows positive Phase 3 results, plans Q1 2027 FDA application

Eli Lilly Grants Compassionate Use Access to Experimental Obesity Drug Retatrutide for Single Patient

Related timelines

Iran War

US Congress

Venture capital funding

Strait of Hormuz blockage

Trump administration